Clinical trials: Elderly Patients (60-75 Years)
Platelet Reactivity
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01463150
- Testing
- Clopidogrel, Prasugrel
- Where
- Greece
- Volunteers
- 27 people
- Sponsor
- University of Patras
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Newly Diagnosed Secondary or High Risk AML
Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
This protocol corresponds to a prospective, multicentre, open label, phase II study designed to evaluate the efficacy of CPX-351 in elderly patients with secondary or high-risk AML.
- Trial name
- LAMVYX (NCT04230239)
- Testing
- CPX-351
- Where
- 12 sites in Spain
- Volunteers
- 59 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)
VAH vs VA in Newly Diagnosed Elderly AML
This is a multicenter, open-label, randomized, controlled phase III clinical trial designed to evaluate the efficacy and safety of the combination of Venetoclax, Azacitidine, and Homoharringtonine (VAH) compared to Venetoclax and…
- Trial name
- NCT07469046
- Testing
- Venetoclax, Azacitidine, Homoharringtonine
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens.
- Trial name
- NCT00788892
- Testing
- CPX-351, Cytarabine, Daunorubicin
- Where
- 28 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia
Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT
This trial is a no profit, prospective, phase II, multicentre, non-randomised, uncontrolled, single group assignment, open label study to evaluate the safety and efficacy of the "chemo-free" combination Venetoclax plus Decitabine…
- Trial name
- NCT04476199
- Testing
- Venetoclax and Decitabine
- Where
- 25 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo